EA202192534A1 - Системы стабилизации и контролируемого высвобождения для лекарственных средств, нестабильных при стерилизации - Google Patents
Системы стабилизации и контролируемого высвобождения для лекарственных средств, нестабильных при стерилизацииInfo
- Publication number
- EA202192534A1 EA202192534A1 EA202192534A EA202192534A EA202192534A1 EA 202192534 A1 EA202192534 A1 EA 202192534A1 EA 202192534 A EA202192534 A EA 202192534A EA 202192534 A EA202192534 A EA 202192534A EA 202192534 A1 EA202192534 A1 EA 202192534A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- stabilization
- controlled release
- release systems
- during sterilization
- unstable during
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Раскрыты алкениламиды сульфатированной гиалуроновой кислоты и их применение для стабилизации и высвобождения лекарственных средств в форме мицеллярных суспензий, которые могут быть введены местным путем и/или местно-регионально, особенно внутрисуставно.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102019000003887A IT201900003887A1 (it) | 2019-03-18 | 2019-03-18 | Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione |
PCT/IB2020/050636 WO2020188365A1 (en) | 2019-03-18 | 2020-01-28 | Stabilisation and controlled-release systems for medicaments unstable on sterilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192534A1 true EA202192534A1 (ru) | 2021-11-29 |
Family
ID=67185559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192534A EA202192534A1 (ru) | 2019-03-18 | 2020-01-28 | Системы стабилизации и контролируемого высвобождения для лекарственных средств, нестабильных при стерилизации |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220241251A1 (ru) |
EP (1) | EP3941948B1 (ru) |
KR (1) | KR20210142146A (ru) |
AU (1) | AU2020243465A1 (ru) |
CA (1) | CA3133901A1 (ru) |
EA (1) | EA202192534A1 (ru) |
ES (1) | ES2943884T3 (ru) |
IT (1) | IT201900003887A1 (ru) |
PL (1) | PL3941948T3 (ru) |
WO (1) | WO2020188365A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113754795B (zh) * | 2021-10-19 | 2023-03-10 | 澳门大学 | 磺酸化透明质酸类化合物、其制备方法及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138572B1 (en) | 1983-10-11 | 1990-07-25 | FIDIA S.p.A. | Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same |
ITPD940054A1 (it) | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
IT1397247B1 (it) | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi agenti regolatori dell'attivita' citochinica |
IT1397246B1 (it) | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica |
IT1402385B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis |
ITPD20120173A1 (it) | 2012-05-31 | 2013-12-01 | Fidia Farmaceutici | "nuovo sistema di rilascio di proteine idrofobiche" |
US20160279108A1 (en) | 2015-02-24 | 2016-09-29 | University Of Kansas | Targeted mtor inhibitors |
US20170065520A1 (en) | 2015-09-09 | 2017-03-09 | Manli International Ltd | Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer |
ITUB20155623A1 (it) | 2015-11-16 | 2017-05-16 | Fidia Farm Spa | Processo migliorato per la produzione di HA solfatato di elevata purezza |
CN105820270A (zh) * | 2016-03-30 | 2016-08-03 | 中国药科大学 | 硫酸化透明质酰脂肪烃胺 |
IT201600117042A1 (it) * | 2016-11-18 | 2018-05-18 | Fidia Farm Spa | Acidi ialuronici solfatati funzionalizzati con dopamina |
-
2019
- 2019-03-18 IT IT102019000003887A patent/IT201900003887A1/it unknown
-
2020
- 2020-01-28 ES ES20707164T patent/ES2943884T3/es active Active
- 2020-01-28 EP EP20707164.8A patent/EP3941948B1/en active Active
- 2020-01-28 KR KR1020217033471A patent/KR20210142146A/ko active Search and Examination
- 2020-01-28 PL PL20707164.8T patent/PL3941948T3/pl unknown
- 2020-01-28 CA CA3133901A patent/CA3133901A1/en active Pending
- 2020-01-28 US US17/440,396 patent/US20220241251A1/en active Pending
- 2020-01-28 AU AU2020243465A patent/AU2020243465A1/en active Pending
- 2020-01-28 EA EA202192534A patent/EA202192534A1/ru unknown
- 2020-01-28 WO PCT/IB2020/050636 patent/WO2020188365A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3133901A1 (en) | 2020-09-24 |
US20220241251A1 (en) | 2022-08-04 |
ES2943884T3 (es) | 2023-06-16 |
KR20210142146A (ko) | 2021-11-24 |
EP3941948B1 (en) | 2023-03-01 |
WO2020188365A1 (en) | 2020-09-24 |
EP3941948A1 (en) | 2022-01-26 |
IT201900003887A1 (it) | 2020-09-18 |
AU2020243465A1 (en) | 2021-11-11 |
PL3941948T3 (pl) | 2023-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003351A (es) | Metodos, composiciones y elementos implantables que comprenden celulas activas. | |
AR107014A1 (es) | Formulación farmacéutica acuosa | |
PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
CY1122038T1 (el) | Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4 | |
WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
CY1124380T1 (el) | Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης | |
MX2023006541A (es) | Formulaciones de dosis fija. | |
CL2016002815A1 (es) | Solución oftálmica acuosa y método para tratar el síndrome del ojo seco | |
BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
CY1123947T1 (el) | Βελτιστοποιημενος υποκινητης rpe65 και βελτιστοποιημενες κωδικοποιητικες αλληλουχιες | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
UY36920A (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral | |
BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
BR112017004393A2 (pt) | formulações de anticorpo | |
NZ746468A (en) | Methods of treating ocular conditions | |
MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
SG10201902407PA (en) | Injectable microparticles for hyper-localized release of therapeutic agents | |
EA202192534A1 (ru) | Системы стабилизации и контролируемого высвобождения для лекарственных средств, нестабильных при стерилизации | |
WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
MX2019003365A (es) | Composiciones de ester de colina de acido lipoico y metodos para estabilizar en productos farmacologicos farmaceuticamente relevantes. | |
EA201890703A1 (ru) | Коллоидные частицы, предназначенные для применения в медицине | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
MX2017013879A (es) | Composiciones que comprenden anakinra. | |
MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. |